May 9, 2013
A team of NIH scientists has developed a new tool to identify broadly neutralizing antibodies (bNAbs) capable of preventing infection by the majority of HIV strains found around the globe, an advance that could help speed HIV vaccine research. Scientists have long studied HIV-infected individuals whose blood shows powerful neutralization activity because understanding how HIV bNAbs develop and attack the virus can yield clues for HIV vaccine design. But until now, available methods for analyzing blood samples did not easily yield specific information about the HIV bNAbs present or the parts of the virus they targeted. In addition, determining where and how HIV bNAbs bind to the virus has been a laborious process involving several complicated techniques and relatively large quantities of blood from individual donors.
The new tool lets scientists determine precisely the HIV bNAbs present in a particular blood sample by analyzing the neutralized HIV strains there. Called neutralization fingerprinting, the tool is a mathematical algorithm (a problem-solving procedure) that exploits the large body of data on HIV bNAbs generated in recent years. The neutralization fingerprint of an HIV antibody is a measurement of which virus strains it can block and with what intensity. Antibodies that target the same portion of the virus tend to have similar fingerprints.
I. Georgiev et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science DOI: 10.1126/science.1233989 (2013).
Peter D. Kwong, Ph.D., chief of the Structural Biology and Structural Bioinformatics Core sections of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases, part of NIH; and John R. Mascola, M.D., acting director of the VRC and chief of its Humoral Immunology section, are available for comment.
No comments have been made.